Floatz logo

Irinotecan

Human Papillomavirus-Related Anal Squamous Cell Carcinoma

Oncolytics BiotechSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Human Papillomavirus-Related Anal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Atezolizumab
Oncolytics Biotech
Phase 2B
Cediranib
M.D. Anderson Cancer Center
Phase 2CCC
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →